1. Biosimilars in the United States: Competition, Savings, and Sustainability (IQVIA, 2020); https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/iqvia-institute-biosimilars-in-the-united-states.pdf
2. Ferris, L. K., Gellad, W. F. & Hernandez, I. JAMA Dermatol. 156, 1136–1138 (2020).
3. Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals (FDA, accessed 6 August 2021); https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process
4. Sarpatwari, A., Barenie, R. & Curfman, G. Clin. Pharmacol. Ther. 105, 92–100 (2019).
5. FDA approvals. Big Molecule Watch (accessed 29 December 2021); https://www.bigmoleculewatch.com/fda-approved-ablas/